COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00JRS
|
|||
| Drug Name |
Lopinavir
|
|||
| Synonyms |
AIDS032937; Aluvia (TN); Aluviran; Kaletra (TN); Koletra; LPV; Lopinavir (JAN/USAN/INN); Lopinavir [USAN:INN:BAN]; RS-346; A 157378; A 157378.0; A-157378-0; A-157378.0; ABT 157378; ABT 378; ABT-378; ABT-378
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Middle East Respiratory Syndrome (MERS) | Preclinical | [1] | Severe acute respiratory syndrome (SARS) | Preclinical | [1] |
| Other Indication | Human immunodeficiency virus infection | Approved | [2] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Company |
Abbott Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C37H48N4O5
|
|||
| Canonical SMILES |
CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O
|
|||
| InChI |
1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1
|
|||
| InChIKey |
KJHKTHWMRKYKJE-SUGCFTRWSA-N
|
|||
| CAS Number |
CAS 192725-17-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
583260, 615079, 826916, 841952, 7848488, 7885634, 7979791, 10225535, 11108093, 11528784, 14912304, 14912305, 26737285, 26757998, 44423527, 46392556, 46508588, 49853992, 50086984, 50096471, 50096475, 50111692, 53812811, 53812974, 56310583, 57335304, 76999753, 87557375, 87557376, 99437252, 103198077, 104178992, 104408196, 123080504, 124757206, 124893167, 125164010, 126522368, 126655919, 126665841, 127310211, 127310212, 127310213, 127338643, 127338644, 127338645, 134337997, 135051036, 136283935, 136367896
|
|||
| ChEBI ID |
CHEBI:31781
|
|||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | MERS-CoV 3C-like proteinase (3CLpro) | Target Info | Inhibitor | [1] |
| Lopinavir, the most readily available 3CLpro inhibitor, has anti-CoV activity in vitro, as well as in MERS-CoV-infected non-human primates and in non-randomized trials of SARS patients. | ||||
| SARS-CoV 3C-like protease (3CLpro) | Target Info | Inhibitor | [1] | |
| Lopinavir, the most readily available 3CLpro inhibitor, has anti-CoV activity in vitro, as well as in MERS-CoV-infected non-human primates and in non-randomized trials of SARS patients. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
| 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.